Some studies have established partial correlations between outcomes with CTLA-4 blockade and peripheral-blood lymphocyte count, markers of T-cell activation, an “inflammatory” tumor microenvironment and maintenance of high-frequency T-cell receptor clonotypes precluding their utilization in clinics [15-17]. Here, CTLA4 is linked to neoplasm.